The research, led by Postat, Merino, Mingarelli and colleagues, demonstrates that when T cells experience the mechanical constraints typical of solid tissues, they switch on a gene-expression profile that mirrors that of bona fide tissue-resident memory T cells, or TRM cells. These cells, marked by canonical signatures such as expression of CD69 and CD103 and the activity of transcription factors including Hobit (encoded by Zfp683) and Blimp-1 (encoded by Prdm1), permanently embed themselves in organs such as skin, lung, gut and liver. They are, in many respects, the immune system’s garrison: they do not circulate, they persist for months or years, and they stand ready to mount rapid defensive responses at the exact sites where pathogens most often enter the body. The new findings suggest that the decision to adopt this resident identity is not governed solely by cytokines and antigen recognition, as the field has long emphasized, but also by the physical texture of the environment itself.

At the heart of the study lies a deceptively simple question with deep implications: how does a T cell know it is in a tissue rather than in blood or lymph? The authors reasoned that the most fundamental difference between these environments is mechanical. Blood is a liquid suspension with low viscosity and little structural resistance, whereas tissues are dense, viscoelastic networks of extracellular matrix, stromal cells and confined interstitial spaces. A T cell navigating a tissue must deform its cytoskeleton, generate traction forces against fibrous substrates, and push its nucleus through gaps far smaller than its own diameter. Each of these activities requires adhesion molecules—most prominently integrins—to physically couple the cell to its surroundings and transmit force across the plasma membrane into the cytoskeleton.

To test whether these forces carry instructive information, the researchers employed a combination of engineered substrates with defined stiffness and ligand density, confinement-based migration assays that force T cells through narrow channels, and transcriptional profiling to capture the genomic consequences of mechanical experience. The logic of the experimental design is important. By varying the mechanical properties of the environment independently of chemical stimuli, the team could ask whether stiffness, confinement and adhesion alone—without any antigen or inflammatory cytokine—were sufficient to bias T cell differentiation. The results indicate that they are. T cells cultured on or migrating through mechanically restrictive environments upregulated key components of the TRM transcriptional program, while cells in mechanically permissive, fluid-like conditions did not.

The mechanistic pathway traced in the study converges on the cytoskeleton and its associated signaling machinery. Mechanosensing in T cells, as in many cell types, depends on integrin engagement and the resulting assembly of focal adhesion-like structures that link extracellular ligands to the actin cytoskeleton. When actomyosin tension builds up—driven by the motor protein non-muscle myosin II—force-sensitive signaling complexes are recruited and activated. The authors show that perturbing this chain, whether by blocking integrin-mediated adhesion, inhibiting myosin-II-dependent contractility, or disrupting actin polymerization, prevents the induction of the tissue-resident memory signature. Conversely, artificially increasing the mechanical challenge presented to T cells enhances the program. This dose-response relationship between physical constraint and TRM-like gene expression is among the most compelling aspects of the work, because it establishes mechanics not as a permissive background factor but as an instructive, titratable cue.

Downstream of the cytoskeleton, the study identifies transcriptional and epigenetic consequences that go well beyond a handful of surface markers. Single-cell and bulk RNA sequencing revealed that mechanically conditioned T cells adopt a broad expression profile encompassing not only CD69 and CD103 but also chemokine receptors, adhesion molecules and survival factors characteristic of the resident memory state. The breadth matters. TRM differentiation has traditionally been modeled as a cascade initiated by antigen recognition and local inflammatory signals—particularly transforming growth factor-β and interleukin-15—that act on transcription factors such as Batf, Hobit and Runx3. The new data suggest a parallel, and potentially cooperating, route in which mechanical input primes the same network. In practical terms, a T cell that has physically struggled through dense matrix arrives at its destination already partway down the road to residency, even before it encounters the cytokine milieu that completes the transformation.

The implications for in vivo immunity are considerable. Tissue-resident memory cells are increasingly recognized as decisive players in protective immunity, vaccine design and cancer immunotherapy. In tumors, TRM-like CD8 T cells are often associated with better clinical outcomes and with responsiveness to immune checkpoint blockade, because these cells occupy the tumor parenchyma where checkpoint inhibitors must ultimately act. If mechanical scanning of tissue is a prerequisite for establishing residency, then the physical architecture of a tumor—its stiffness, its matrix density, its degree of stromal confinement—may directly influence how effectively adoptively transferred T cells or CAR-T cells take up long-term residence and sustain anti-tumor activity. This could help explain a persistent puzzle in cell therapy: why T cells that persist and function robustly in blood sometimes fail to engraft durably within solid tumors. The new study raises the possibility that engineering T cells with enhanced mechanosensing capacity, or preconditioning them mechanically before infusion, could improve their ability to implant and persist in hostile tissue environments.

The findings also resonate with vaccine strategy. Intranasal and intradermal vaccination approaches that deliver antigen directly to barrier tissues are known to generate superior TRM responses compared with systemic immunization. The mechanistic framework proposed here adds a new dimension to that observation: the local tissue microenvironment may contribute to TRM generation not only through its soluble signals but through its physical structure. A vaccine designed to exploit this could, in principle, pair antigen delivery with biomaterials engineered to present the right mechanical context, coaxing T cells into residency at the anatomical sites where protection is needed most.

The study’s technical achievements deserve emphasis. Distinguishing mechanical effects from confounding chemical signals is notoriously difficult, because altering substrate stiffness often changes how cells spread, adhere and therefore encounter immobilized ligands. The authors navigated this by systematically controlling ligand density and presenting mechanical cues in defined geometries, including microfabricated constrictions that mimic interstitial migration without altering soluble signaling. Combining these engineered systems with high-resolution transcriptional profiling allowed them to move from correlation to mechanism, demonstrating causality through pharmacological and genetic disruption of the mechanotransduction machinery. The consistency between in vitro findings and the behavior of T cells in tissues lends the work translational weight.

There remain open questions that will likely drive the next phase of research. How durable is the mechanically induced program, and does it require reinforcement by cytokines to yield fully functional, long-lived TRM cells? Which of the many mechanosensitive pathways—integrin-linked kinase signaling, the hippo pathway, calcium entry through mechanosensitive ion channels, or nuclear deformation-driven chromatin changes—are essential versus redundant? And how do mechanical cues interact with T cell receptor signaling, given that antigen recognition itself involves physical forces at the immunological synapse? The interplay between antigen-specific and tissue-specific mechanical signals could prove central to understanding why only some tissue-scanning T cells commit to residency while others re-enter circulation.

What the study establishes beyond reasonable doubt is a conceptual shift. Immunology has been dominated for decades by the logic of molecular recognition—receptor and ligand, cytokine and receptor, checkpoint and antibody. The new work insists that the mechanical landscape of the body belongs alongside these molecular signals as a first-class determinant of immune cell fate. T cells, in this view, are not merely biochemical computers but physical entities whose differentiation history is written in part by the forces they have endured. Every crawl through collagen, every squeeze between endothelial cells, every tug against a fibronectin fiber leaves a mark on the genome. For a discipline now racing to engineer immune cells with precision, recognizing that the body’s architecture is itself an instructor may prove to be one of the more consequential lessons of the decade.

For decades, the mechanical properties of the extracellular matrix (ECM) — the complex network of proteins and molecules surrounding cells — have been recognized as influential in regulating cellular behavior. Changes in ECM stiffness are known to impact cell morphology, migration, and differentiation. However, the precise molecular players that translate these mechanical signals into biochemical responses within cancer cells have remained elusive. This study identifies TYK2 as a pivotal mediator that links ECM stiffness to metastatic potential in breast cancer, revealing a mechanoresponsive switch that influences cancer cell invasiveness.

At the heart of these findings is the localization and activity of TYK2. Under conditions of low ECM stiffness, TYK2 is anchored to the plasma membrane of breast cells, where it closely associates with E-cadherin, a cell adhesion molecule essential for maintaining tissue architecture and cellular cohesion. This co-localization reinforces cell-cell adhesion, effectively suppressing the ability of cancer cells to detach and invade surrounding tissues. In contrast, increased ECM rigidity disrupts this membrane localization, causing TYK2 to redistribute throughout the cytoplasm and become inactivated. This redistribution weakens cellular adhesion, facilitating enhanced motility and invasiveness—a hallmark of metastatic progression.

The biological relevance of these mechanistic insights was demonstrated through rigorous in vivo experimentation. Mouse models genetically engineered to mirror human breast cancer displayed increased tumor invasiveness and metastatic dissemination when TYK2 activity was pharmacologically inhibited. These results underscore the protective role of membrane-bound TYK2 in guarding against metastasis, spotlighting the protein as an endogenous barrier to cancer spread modulated by mechanical cues in the tumor microenvironment.

This study’s revelations also raise important clinical considerations. TYK2 inhibitors have been explored as promising therapeutics for a variety of autoimmune and inflammatory disorders given their role in modulating inflammatory signaling pathways. However, the dualistic function of TYK2—as both an immune regulator and a metastasis suppressor—introduces a potential therapeutic paradox. Patients undergoing treatment with TYK2 inhibitors for autoimmune diseases might inadvertently elevate their risk for breast cancer invasion and metastasis, especially if pre-existing noninvasive tumors are present. Accordingly, the researchers advocate for enhanced vigilance and breast cancer screening protocols in patients receiving TYK2-targeted therapy.

Crucially, this work shifts the paradigm by emphasizing the mechanical microenvironment’s influence in cancer progression. Tumors are not solely governed by genetic and biochemical factors but are also sculpted by physical forces within their niche. By elucidating how ECM stiffness governs TYK2 activity and thereby metastasis, the study opens avenues for therapeutic interventions that could modulate tissue mechanics or restore TYK2’s protective membrane association.

The molecular underpinnings of TYK2’s function in mechanotransduction involve its interaction with key adhesion complexes and downstream signaling cascades. When tethered to the membrane, TYK2 likely participates in stabilizing adherens junctions via cross-talk with E-cadherin and associated cytoskeletal components. Disruption of this spatial organization by increased matrix stiffness interferes with signaling pathways essential for maintaining epithelial integrity, mirroring processes such as epithelial-to-mesenchymal transition (EMT), which is instrumental in cancer metastasis.

Further analysis of tumor samples from patients revealed a consistent pattern: higher ECM stiffness correlated with diffuse cytoplasmic distribution of TYK2 and decreased E-cadherin co-localization. This histological evidence supports the translational relevance of the mouse models and provides a predictive marker that could be leveraged for diagnostic and prognostic purposes. Strategies aimed at restoring or mimicking low-stiffness microenvironments might reinstate the metastasis-suppressive function of TYK2, holding promise for combinational therapies.

The comprehensive nature of this study, incorporating molecular biology, biophysics, animal modeling, and human tissue analysis, exemplifies the multidisciplinary approach required to tackle complex diseases like cancer. The identification of TYK2 as a mechanoresponsive gatekeeper that modulates metastatic potential underscores the necessity of integrating biomechanical factors into cancer research and treatment paradigms.

Looking ahead, therapeutic innovation may stem from drugs designed to enhance TYK2 membrane localization or preserve its activity in stiff tumor environments, thereby curbing cancer cell dissemination. Such approaches would complement existing treatments targeting genetic and immunologic pathways, offering a holistic strategy to inhibit metastasis and improve patient outcomes. Furthermore, this research calls for a reassessment of current drug development programs involving TYK2 inhibitors, urging a nuanced balance between autoimmune disease management and cancer risk mitigation.

Ultimately, the study published in Nature Communications advances our understanding of the dynamic interplay between cellular mechanics and cancer biology, championing TYK2 as a critical nexus in breast cancer metastasis control. As this knowledge permeates clinical practice, it may transform breast cancer treatment, prognosis, and screening, heralding a new era of precision medicine shaped by the physical properties of tumor microenvironments.

Subject of Research: Mechanotransduction in breast cancer; role of TYK2 in metastasis suppression

Article Title: TYK2 mediates extracellular matrix stiffness to suppress breast cancer metastasis

News Publication Date: Not provided

Web References:
https://www.nature.com/articles/s41467-026-70518-9

References: Funded in part by The National Cancer Institute (R01CA174869, RO1CA262794, R01CA268179, and R01CA236386) and the American Association of Cancer Research (21-80-44-YANG)

Image Credits: UC San Diego Health Sciences

Keywords: Breast cancer, metastasis, mechanotransduction, TYK2, extracellular matrix stiffness, cancer microenvironment, cell adhesion, E-cadherin, tumor progression, cancer invasion, pharmacology, cancer therapy